Drug Profile
Research programme: asthma and inflammation therapeutics - AbbVie
Alternative Names: ABT-362Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Class
- Mechanism of Action Interleukin 13 inhibitors; Interleukin 18 inhibitors; Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase inhibitors; Janus kinase-2 inhibitors; P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Immunological disorders; Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Immunological-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA